While the specific combination of a PI3K inhibitor and valemetostat has not yet been tested in patients, our colony assays on mouse bone marrow cells and healthy donor CD34 cells, and combination drug treatment in multiple mouse AML models suggest that a therapeutic window should be achievable. This evidence concerns the gene PIK3CA and acute myeloid leukemia.